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January 2017 Abstracts S333Results: Median time between CT scan and surgery was
18 days (range 1-48). The analysis revealed a moderate
correlation between CT tumor volume and weight
(p¼0.001, correlation coefficient 0.58, CT volume and
tumor volume at surgery showed strong correlation
(p¼0.001, correlation coefficient 0.65). No significant
correlation was observed between cT stage and tumor
weight (p¼0.1, correlation coefficient 0.31), but a mod-
erate correlation between cT stage and CT volume
(p¼0.001, correlation coefficient 0.58) as well as spec-
imen volume (p¼0.008, correlation coefficient 0.58).
There was a moderate correlation of tumor weight with
pT stage (p¼0.02, correlation coefficient 0.42), but no
correlation of CT volume (p¼0.1, correlation coefficient
0.31) as well as specimen volume with the pT stage
(p¼0.2, correlation coefficient 0.32).
Conclusion: The correlation between preoperatively
assessed CT tumor volume and volume of the resected
specimen showed a strong correlation. To assess the
prognostic role of CT measured tumor volume a corre-
lation to prognosis has to be performed before imple-
mentation as a new T-factor.
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Background: Monoclonal Antibodies (mAbs) against the
Epidermal Growth Factor Receptor (EGFR) in association
with platinum-based doublet chemotherapy have
emerged as a potential first-line treatment option for
advanced non-small cell lung cancer (NSCLC). This study
was conducted to systematically review available data
and evaluate the efficacy and toxicity of anti-EGFR mAbs
plus chemotherapy vs chemotherapy alone for advanced
NSCLC.
Methods: We carried out a search on network data-
bases and oncology conference abstracts for studies
between 1990 and January 2016. Only prospective
randomized clinical trials were included. Primary
endpoints were overall survival (OS) and toxicity fre-
quency. Secondary endpoints were progression-free
survival (PFS) and overall response rate (ORR). Sub-
group analysis was performed assessing histological
subtypes, EGFR protein expression by immunohisto-
chemistry (IHC), EGFR gene copy number by fluores-
cence in-situ hybridization (FISH), EGFR mutation
status, and smoking status.
Results: Seven studies (2 with necitumumab and 5
with cetuximab) were included with 5,057 patients.
Compared to chemotherapy alone, significant benefits
were demonstrated by the addition of anti-EGFR mAb
to chemotherapy in OS (HR 0.90; 95%CI 0.84-0.95),
PFS (HR 0.93; 95%CI 0.87-0.98), and ORR (OR 1.27;
95%CI 1.06-1.51). In subgroup analyses, the associa-
tion of anti-EGFR mAb was associated with improved
OS among patients with squamous histology (HR 0.84;
95%CI 0.76-0.92), tumours with high EGFR expression
by IHC (HR 0.83; 95%CI 0.70-0.98), and smokers (HR
0.87; 95%CI 0.79-0.96). Patients with squamous his-
tology and high EGFR expression by IHC achieved the
highest benefit with the association (HR 0.71; 95%CI
0.59-0.86). The OS with the association also seemed to
be higher in EGFR FISH negative and in EGFR wild-type
tumours, but without statistical significance. Chemo-
therapy plus anti-EGFR mAb caused more grade 3 or
worse adverse events (OR 1.73; 95%CI 1.50-2.00),
remarkedly these known to be associated with anti-
EGFR therapy, such as acne-like rash (OR 34.13; 95%CI
16.40-71.00) and hypomagnesemia (OR 6.23; 95%CI
3.04-12.77).
Conclusion: Anti-EGFR therapy plus platinum-based
doublet chemotherapy as first-line treatment demon-
strated significant efficacy benefits with acceptable
toxicity for advanced NSCLC. This benefit is more
expressive among squamous histology with high EGFR
S334 Journal of Thoracic Oncology Vol. 12 No. 1Sexpression. EGFR protein expression by IHC seems to be
a predictive marker for survival in the association group.
Further research is needed to corroborate these findings.
Keywords: anti-EGFR, biomarker, Targeted therapy, In-
dividual Medicine
OA23.02
Efficacy and Safety of Necitumumab
Continuation Monotherapy in Patients
with EGFR-Expressing Tumors in SQUIRE,
a Phase 3 StudyTudor Ciuleanu,1 Mark Socinski,2 Coleman Obasaju,3
Alexander Luft,4 Aleksandra Szczęsna,5
Rodryg Ramlau,6 Beatrix Bálint,7 Olivier Molinier,8
Henrik Depenbrock,9 Shivani Nanda,10
Luis Paz-Ares,11 Nick Thatcher12 1Institute of Oncology
Ion Chiricuta and Umf Iuliu Hatieganu, Cluj Napoca/
Romania, 2Florida Hospital Cancer Institute, Orlando/FL/
United States of America, 3Eli Lilly and Company,
Indianapolis/IN/United States of America, 4Leningrad
Regional Clinical Hospital, St. Petersburg/Russian
Federation, 5Regional Lung Disease Hospital, Otwock/
Poland, 6Department of Oncology, Poznan University of
Medical Sciences, Poznan/Poland, 7Csongrád County
Hospital of Chest Diseases, Deszk/Hungary, 8Hospital
Center, Le Mans/France, 9Medical Oncology, Lilly
Deutschland GmbH, Bad Homburg/Germany, 10Statistics-
Oncology, Eli and Company, Bridgewater/NJ/United States
of America, 11University Hospital Virgen Del Rocio, Seville/
Spain, 12The Christie Hospital, Manchester/United
Kingdom
Background: SQUIRE (NCT00981058) demonstrated
adding necitumumab (N) to gemcitabine/cisplatin (GC)
improved survival in patients with Stage IV squamous
NSCLC (SQ-NSCLC). Retrospective analysis revealed
consistent treatment effect in favor of patients receiving
N monotherapy as continuation after chemotherapy (CT)
(GC+N continuation patients) versus continuation ther-
apy-eligible GC arm patients (GC non-progressors). In
the EU, N is approved for patients with EGFR-expressing
tumors. We repeated the analysis in this patient
population.
Methods: Patients with Stage IV SQ-NSCLC were ran-
domized 1:1 for 6 cycles of G (1250 mg/m2 iv, Days [d]
1,8) and C (75 mg/m2 iv, d1) either with or without N
(800 mg iv, d1,8). Patients in GC+N without progression
continued N until progressive disease (PD). SQUIRE
included mandatory tissue collection. EGFR protein
expression was assessed by IHC in a central lab
(Dako EGFR PharmDx kit). Analyses were done inEGFR-expressing patients (EGFR >0). Patients who
received 4 cycles of CT without PD were included.
Overall survival (OS) and progression-free survival (PFS)
were calculated by Kaplan-Meier method. 95% CIs and
hazard ratios estimated using stratified Cox proportional
hazards model.
Results: Of 1093 patients (ITT population), 982 patients
(89.8%) had evaluable IHC assay results; 935/982
(95.2%) had EGFR>0. GC+N arm continuation therapy
patients included 228 patients with EGFR>0 and 194
patients (EGFR>0) were GC arm non-progressors.
Baseline characteristics were similar except gender
(Males: 81% in GC+N vs 91% in GC arm). CT exposure
was balanced. Median OS from randomization in GC+N
vs GC was 16.1 vs 14.9 months; HR 0.76 (95% CI, 0.61,
0.95). Median PFS in GC+N vs GC was 7.4 vs 6.9 months;
HR 0.81 (95% CI, 0.66, 1.00).
Conclusion: In patients with EGFR-expressing tumors, a
consistent treatment effect in favor of GC+N continuation
maintenance compared to GC non-progressors was
observed, similar to ITT population with no unexpected
increases in AEs.
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